NANETS Regional NET Education Multidisciplinary Management of NET Cancers CME/CE Certified Activity is September 15th in New Brunswick, NJ

NANETS Regional NET Education Multidisciplinary Management of NET Cancers CME/CE Certified Activity is Saturday, September 15, 2018 from 7:30 am – 4:00 pm at Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, New Jersey.

This CME/CE Certified Activity is jointly Provided by Rutgers Cancer Institute of New Jersey, Rutgers Biomedical and Health Sciences and North American Neuroendocrine Tumor Society.

Overview

Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has increased over the last ten years. As this is a rare disease, clinicians often do not know how to implement the appropriate care plan and until the last ten years there was great variability in terms of treatment. The diagnosis, treatment and management of NETs are time consuming, complex and require a multidisciplinary approach. Many healthcare providers who face these challenges are not adequately equipped in their knowledge or experience optimally manage NET disease.

The field of NET research has been evolving with new drug approvals and treatment modalities. In addition, experts in the field of NET disease have continued to develop strategies to improve diagnosis, treatment and management of NET cancers. It is through convening professionals in the areas of oncology, gastroenterology, pulmonology, surgery, radiology and allied fields that the awareness and understanding of NET diseases will expand, resulting in better treatment for NET patients.

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Upon completion of this activity, participants should be better able to:
◾Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
◾Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
◾Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
◾Recognize the clinical features associated with carcinoid syndrome
◾Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
◾Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors
◾Evaluate the latest diagnostic and treatment options for patients with carotid artery stenosis

Michael Nissenblatt, MD, CJOC Division of RCCA will moderate a symposium on Carcinoid Syndrome.

For more information or to register, visit nanets.net.